Q2 Earnings Forecast for Electromed Issued By Roth Capital

Electromed, Inc. (NYSE:ELMD) – Stock analysts at Roth Capital decreased their Q2 2026 EPS estimates for shares of Electromed in a research report issued to clients and investors on Wednesday, November 12th. Roth Capital analyst K. Bauser now expects that the company will post earnings per share of $0.25 for the quarter, down from their previous forecast of $0.27. Roth Capital has a “Buy” rating and a $36.00 price objective on the stock. Roth Capital also issued estimates for Electromed’s Q3 2026 earnings at $0.25 EPS, FY2026 earnings at $1.05 EPS and FY2027 earnings at $1.25 EPS.

Other equities analysts have also issued reports about the company. Lake Street Capital assumed coverage on Electromed in a research note on Wednesday, August 27th. They issued a “buy” rating and a $36.00 target price on the stock. Loop Capital set a $36.00 price target on shares of Electromed in a report on Wednesday, August 27th. Finally, Zacks Research cut shares of Electromed from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Electromed currently has a consensus rating of “Buy” and an average target price of $36.50.

Electromed Trading Down 5.0%

Shares of Electromed stock traded down $1.31 during trading on Friday, hitting $25.04. The stock had a trading volume of 7,093 shares, compared to its average volume of 77,355. The firm has a market cap of $209.74 million, a price-to-earnings ratio of 33.39 and a beta of 0.40. Electromed has a 12 month low of $17.73 and a 12 month high of $35.56. The business’s 50-day moving average is $24.60 and its 200 day moving average is $21.98.

Hedge Funds Weigh In On Electromed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC boosted its stake in shares of Electromed by 25.2% during the first quarter. Acadian Asset Management LLC now owns 267,975 shares of the company’s stock valued at $6,388,000 after purchasing an additional 53,872 shares during the period. Cubist Systematic Strategies LLC increased its stake in shares of Electromed by 246.7% in the first quarter. Cubist Systematic Strategies LLC now owns 32,921 shares of the company’s stock worth $785,000 after buying an additional 23,425 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Electromed in the first quarter worth $350,000. Goldman Sachs Group Inc. raised its holdings in Electromed by 9.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 32,281 shares of the company’s stock valued at $770,000 after buying an additional 2,672 shares during the last quarter. Finally, State of Wyoming purchased a new stake in Electromed during the 1st quarter valued at $48,000. 40.82% of the stock is currently owned by institutional investors.

Insider Activity at Electromed

In other news, Director Andrew Summers sold 62,561 shares of the business’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $24.32, for a total value of $1,521,483.52. Following the completion of the sale, the director owned 3,153 shares of the company’s stock, valued at approximately $76,680.96. The trade was a 95.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 10.50% of the company’s stock.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.